Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enteric vaccines for pediatric use. Workshop summary.

Richard I Walker1, Lillian L Van De Verg, Robert H Hall

  • 1Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike (HFM-425), Rockville, MD 20851-1448, USA. walkerri@cber.fda.gov

Vaccine
|November 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity.

Frontiers in immunology·2026
Same author

Conserved antigens for enteric vaccines.

Vaccine·2025
Same author

Special Issue on Enterotoxigenic <i>Escherichia coli</i> (ETEC) Vaccines: ETEC Infection and Vaccine-Mediated Immunity.

Microorganisms·2024
Same author

Vaccine value profile for enterotoxigenic Escherichia coli (ETEC).

Vaccine·2023
Same author

Exploring Food Allergy Management and Food-Related Social Occupations in Elementary School-Aged Children.

OTJR : occupation, participation and health·2023
Same author

Oral inactivated whole cell vaccine for mucosal immunization: ETVAX case study.

Frontiers in immunology·2023
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
Same journal

Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.

Vaccine·2026
Same journal

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.

Vaccine·2026
Same journal

Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011-2020.

Vaccine·2026
Same journal

Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial.

Vaccine·2026
See all related articles

Developing enteric vaccines is crucial for reducing child mortality from diarrheal diseases in less developed countries (LDCs). A workshop confirmed no major roadblocks exist for creating these vital pediatric vaccines.

Area of Science:

  • Global Health
  • Vaccinology
  • Pediatric Infectious Diseases

Background:

  • Diarrheal diseases are a leading cause of mortality in children under five in less developed countries (LDCs).
  • Vaccine development presents a critical near-term strategy to address this global health challenge.

Framework:

  • The workshop focused on critical aspects of enteric vaccine advancement.
  • Key areas included research and development needs, regulatory pathways, and business considerations.
  • Past experiences with enteric vaccine development and implementation were also reviewed.

Implementation:

  • Discussants identified no insurmountable obstacles to progressing enteric vaccine initiatives.
  • The potential exists for successful development and deployment of these vaccines.

Related Experiment Videos

  • Adequate support is crucial for realizing the availability of enteric vaccines for children.

    • Implications:

    • Successful implementation of enteric vaccines could significantly reduce child mortality from diarrheal diseases.
    • This advancement holds promise for improving pediatric health outcomes in resource-limited settings.
    • Further research and investment are warranted to overcome challenges and ensure vaccine accessibility.